Immunome, Inc. (IMNM) — Financial statements
Income statement, balance sheet, and cash flow for Immunome, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 7↓23.2% | 9↓35.5% | 14 | 0.00 | 0.00 | |
| Cost of Revenue | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 4↓55.9% | 9↓35.5% | 14 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 174↑34.6% | 130↑461.1% | 23↓0.8% | 23↑64.9% | 14 | |
| General & Administrative Expenses | 44↑32.8% | 33↑67.7% | 20↑44.2% | 14↑22.9% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 44↑32.8% | 33↑67.7% | 20↑44.2% | 14↑22.9% | 11 | |
| Other Expenses | 0.00↓100.0% | 152↑88.5% | 81 | 0.00 | 0.00 | |
| Operating Expenses | 218↓30.7% | 315↑154.8% | 124↑234.8% | 37↑46.4% | 25 | |
| Total Costs & Expenses | 221↓29.8% | 315↑154.8% | 124↑234.8% | 37↑46.4% | 25 | |
| Operating Results | ||||||
| Operating Income | -214↑30.0% | -306↓179.2% | -110↓196.8% | -37↓46.4% | -25 | |
| Depreciation & Amortization | 3↑40.6% | 2↑188.7% | 0.73↑15.4% | 0.63↓16.4% | 0.76 | |
| EBITDA | -211↓39.5% | -151↓440.6% | -28↑22.8% | -36↓48.3% | -24 | |
| EBIT | -214↓39.5% | -153↓434.2% | -29↑22.1% | -37↓46.4% | -25 | |
| Interest & Other Income | ||||||
| Net Interest Income | 12↓8.7% | 13↑371.3% | 3 | 0.00 | 0.00 | |
| Interest Income | 12↓8.7% | 13↑371.3% | 3↑54380.0% | 0.01↓50.0% | 0.01 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.01↓50.0% | 0.01 | |
| Non-Operating Income | 0.00↑100.0% | -152↓88.5% | -81 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↓86.6% | 13↑371.3% | 3↑54380.0% | 0.01↓99.0% | 0.49 | |
| Income Before Tax | -212↑27.5% | -293↓174.3% | -107↓189.5% | -37↓49.3% | -25 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -212↑27.5% | -293↓174.3% | -107↓189.5% | -37↓49.3% | -25 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -212↑27.5% | -293↓174.3% | -107↓189.5% | -37↓49.3% | -25 | |
| Bottom-Line Net Income | -212↑27.5% | -293↓174.3% | -107↓184.7% | -38↓51.8% | -25 | |
| EPS (Basic) | -2.43↑51.4% | -5.00↑7.1% | -5.38↓74.1% | -3.09↓44.4% | -2.14 | |
| EPS (Diluted) | -2.43↑51.4% | -5.00↑7.1% | -5.38↓74.1% | -3.09↓44.4% | -2.14 | |
| Weighted Average Shares | 87↑49.0% | 59↑195.5% | 20↑63.6% | 12↑5.1% | 12 | |
| Weighted Average Diluted Shares | 87↑49.0% | 59↑195.5% | 20↑63.6% | 12↑5.1% | 12 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.